This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Pradaxa Capsules, 110 mg of Boehringer Ingelheim Pharmaceuticals
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Report highlights significant improvements in adolescent well-being in India
Campaign launched to spread awareness regarding dengue prevention and control
dsm-firmenich decided to de-prioritize certain business segments, including the MEG-3 business
Subscribe To Our Newsletter & Stay Updated
